{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T14:13:28Z","timestamp":1758636808990,"version":"3.37.3"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T00:00:00Z","timestamp":1715817600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,25]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>This systematic review assessed the efficacy and safety of abatacept in patients with systemic juvenile idiopathic arthritis (JIA).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Studies published between 2000 and 2021 were searched using PubMed, Embase, Cochrane, Ichushi-Web, and clinical trial registries. The risk of bias was assessed according to the manual for development clinical practice guidelines by Minds, a project to promote evidence-based medicine in Japan.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Seven observational studies were included. American College of Rheumatology pediatric 30\/50\/70 responses at 3, 6, and 12\u2009months were 64.8%\/50.3%\/27.9%, 85.7%\/71.4%\/42.9%, and 80.0%\/50.0%\/40.0%, respectively. Outcomes on systemic symptoms, joint symptoms, and activities of daily living were not obtained. No macrophage activation syndrome or infusion reaction occurred. Serious infection occurred in 2.6% of cases.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Abatacept improved the disease activity index. In addition, abatacept was as safe as interleukin-6 (IL-6) and IL-1 inhibitors. However, both the efficacy and safety data in this systematic review should be reviewed with caution because their quality of evidence is low or very low. Further studies are needed to confirm the efficacy and safety of abatacept for systemic JIA, especially its efficacy on joint symptoms.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/mr\/roae046","type":"journal-article","created":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T14:19:14Z","timestamp":1715782754000},"page":"167-173","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy and safety of abatacept for systemic juvenile idiopathic arthritis: A systematic review"],"prefix":"10.1093","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9827-3503","authenticated-orcid":false,"given":"Kenichi","family":"Nishimura","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Yokohama City University Graduate School of Medicine , Kanagawa,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0247-7729","authenticated-orcid":false,"given":"Takashi","family":"Ishikawa","sequence":"additional","affiliation":[{"name":"Division of Immunology, National Center for Child Health and Development , Tokyo,","place":["Japan"]},{"name":"Department of Pediatrics, Jikei University School of Medicine , Tokyo,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nami","family":"Okamoto","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Osaka Medical and Pharmaceutical University , Osaka,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiji","family":"Akamine","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Rheumatology, Tokyo Metropolitan Children\u2019s Medical Center , Tokyo,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natsumi","family":"Inoue","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, School of Medicine, Institute of Medical, Pharmaceutical, and Health Sciences, Kanazawa University , Ishikawa,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoshi","family":"Irabu","sequence":"additional","affiliation":[{"name":"Department of Child Health and Development, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University , Tokyo,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kentaro","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Kyoto University Graduate School of Medicine , Kyoto,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Keino","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Kyorin University School of Medicine , Tokyo,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayo","family":"Kojima","sequence":"additional","affiliation":[{"name":"Nagoya City University , Aichi,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Kubo","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Kyoto Prefectural University of Medicine Graduate School of Medical Science , Kyoto,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuichi","family":"Maruyama","sequence":"additional","affiliation":[{"name":"Department of Vision Informatics, Graduate School of Medicine, Osaka University , Osaka,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mao","family":"Mizuta","sequence":"additional","affiliation":[{"name":"Department of Pediatric Rheumatology, Hyogo Prefectural Kobe Children\u2019s Hospital , Hyogo,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kosuke","family":"Shabana","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Osaka Medical and Pharmaceutical University , Osaka,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaki","family":"Shimizu","sequence":"additional","affiliation":[{"name":"Department of Child Health and Development, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University , Tokyo,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuko","family":"Sugita","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Osaka Medical and Pharmaceutical University , Osaka,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukiko","family":"Takakuwa","sequence":"additional","affiliation":[{"name":"Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine , Kanagawa,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Takanashi","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine , Tokyo,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Takase","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology & Visual Science, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University , Tokyo,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Umebayashi","sequence":"additional","affiliation":[{"name":"Department of Rheumatism, Infectious Disease, Miyagi Children\u2019s Hospital , Miyagi,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natsuka","family":"Umezawa","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University , Tokyo,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shingo","family":"Yamanishi","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Tokyo Yamate Medical Center , Tokyo,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuko","family":"Yamazaki","sequence":"additional","affiliation":[{"name":"Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine , Kanagawa,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masato","family":"Yashiro","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Okayama University Hospital , Okayama,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Yasumi","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Kyoto University Graduate School of Medicine , Kyoto,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaaki","family":"Mori","sequence":"additional","affiliation":[{"name":"Lifetime Clinical Immunology, Tokyo Medical and Dental University , Tokyo,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,5,16]]},"reference":[{"key":"2025020515445187500_R1","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0140-6736(07)60363-8","article-title":"Juvenile idiopathic arthritis","volume":"369","author":"Ravelli","year":"2007","journal-title":"Lancet"},{"key":"2025020515445187500_R2","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1002\/acr.21625","article-title":"Consensus treatment plans for new-onset systemic juvenile idiopathic arthritis","volume":"64","author":"DeWitt","year":"2012","journal-title":"Arthritis Care Res"},{"key":"2025020515445187500_R3","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1056\/NEJMoa035075","article-title":"Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig","volume":"349","author":"Kremer","year":"2003","journal-title":"N Engl J Med"},{"key":"2025020515445187500_R4","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0140-6736(08)60998-8","article-title":"Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial","volume":"372","author":"Ruperto","year":"2008","journal-title":"Lancet"},{"key":"2025020515445187500_R5","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1002\/art.39234","article-title":"Long-term safety, efficacy, and quality of life in patients with juvenile idiopathic arthritis treated with intravenous abatacept for up to seven years","volume":"67","author":"Lovell","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2025020515445187500_R6","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/art.42037","article-title":"2021 American College of Rheumatology Guideline for the treatment of juvenile idiopathic arthritis: therapeutic approaches for oligoarthritis, temporomandibular joint arthritis, and systemic juvenile idiopathic arthritis","volume":"74","author":"Onel","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"2025020515445187500_R7","first-page":"1","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2025020515445187500_R8","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1002\/1529-0131(199707)40:7<1202::AID-ART3>3.0.CO;2-R","article-title":"Preliminary definition of improvement in juvenile arthritis","volume":"40","author":"Giannini","year":"1997","journal-title":"Arthritis Rheum"},{"key":"2025020515445187500_R9","first-page":"2290","article-title":"Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis","volume":"31","author":"Wallace","year":"2004","journal-title":"J Rheumatol"},{"key":"2025020515445187500_R10","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/art.1780380107","article-title":"Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis","volume":"38","author":"Prevoo","year":"1995","journal-title":"Arthritis Rheum"},{"key":"2025020515445187500_R11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13075-017-1462-2","article-title":"Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry","volume":"19","author":"Horneff","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"2025020515445187500_R12","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1002\/art.1780371209","article-title":"Measurement of health status in children with juvenile rheumatoid arthritis","volume":"37","author":"Singh","year":"1994","journal-title":"Arthritis Rheum"},{"key":"2025020515445187500_R13","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1467-985X.2008.00547.x","article-title":"Bias modelling in evidence synthesis","volume":"172","author":"Turner","year":"2009","journal-title":"J R Stat Soc Ser A Stat Soc"},{"author":"Japan Council for Quality Health Care.","key":"2025020515445187500_R14","article-title":"Minds Guideline Library"},{"key":"2025020515445187500_R15","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"2025020515445187500_R16","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jclinepi.2018.01.012","article-title":"GRADE guidelines: 18. How ROBINS-I and other tools to assess risk of bias in nonrandomized studies should be used to rate the certainty of a body of evidence","volume":"111","author":"Sch\u00fcnemann","year":"2019","journal-title":"J Clin Epidemiol"},{"key":"2025020515445187500_R17","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2013-eular.3016","article-title":"The efficacy and safety of abatacept (orencia) in patients with active juvenile idiopathic arthritis (JIA)","volume":"72","author":"Zholobova","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2025020515445187500_R18","first-page":"2628","article-title":"Subcutaneous abatacept in patients aged 2-17 years with juvenile idiopathic arthritis and inadequate response to biologic or non-biologic disease-modifying antirheumatic drugs: results over 24 months by juvenile idiopathic arthritis disease category","volume":"70","author":"Ruperto","year":"2018","journal-title":"Arthritis Rheum"},{"key":"2025020515445187500_R19","article-title":"Severe adverse events with use of biologic therapy in patients with systemic juvenile idiopathic arthritis: single-center study","volume":"15","author":"Russo","year":"2017","journal-title":"Pediatr Rheumatol"},{"key":"2025020515445187500_R20","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1002\/art.40466","article-title":"Subcutaneous abatacept in patients with polyarticular-course juvenile idiopathic arthritis: results from a Phase III Open-Label Study","volume":"70","author":"Brunner","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"2025020515445187500_R21","first-page":"521","article-title":"The risk of hospitalized infection associated with initiation of abatacept versus TNF inhibitors in juvenile idiopathic arthritis","volume":"68","author":"Beukelman","year":"2016","journal-title":"Arthritis Rheum"},{"key":"2025020515445187500_R22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/rmdopen-2014-000036","article-title":"Biological treatment in systemic juvenile idiopathic arthritis: achievement of inactive disease or clinical remission on a first, second or third biological agent","volume":"1","author":"Woerner","year":"2015","journal-title":"RMD Open"},{"key":"2025020515445187500_R23","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0140-6736(08)60454-7","article-title":"Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial","volume":"371","author":"Yokota","year":"2008","journal-title":"Lancet"},{"key":"2025020515445187500_R24","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1112802","article-title":"Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis","volume":"367","author":"De Benedetti","year":"2012","journal-title":"N Engl J Med"},{"key":"2025020515445187500_R25","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1056\/NEJMoa1205099","article-title":"Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis","volume":"367","author":"Ruperto","year":"2012","journal-title":"N Engl J Med"},{"key":"2025020515445187500_R26","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1136\/annrheumdis-2018-213150","article-title":"Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: results from the 5-year long-term extension of the phase III pivotal trials","volume":"77","author":"Ruperto","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2025020515445187500_R27","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1002\/art.23291","article-title":"Interleukin-17-producing T cells are enriched in the joints of children with arthritis, but have a reciprocal relationship to regulatory T cell numbers","volume":"58","author":"Nistala","year":"2008","journal-title":"Arthritis Rheum"},{"key":"2025020515445187500_R28","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1002\/acr.23277","article-title":"Effect of biologic therapy on clinical and laboratory features of macrophage activation syndrome associated with systemic juvenile idiopathic arthritis","volume":"70","author":"Schulert","year":"2018","journal-title":"Arthritis Care Res"},{"key":"2025020515445187500_R29","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1136\/annrheumdis-2015-207818","article-title":"Tocilizumab in systemic juvenile idiopathic arthritis in a real-world clinical setting: results from 1 year of postmarketing surveillance follow-up of 417 patients in Japan","volume":"75","author":"Yokota","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2025020515445187500_R30","first-page":"129","article-title":"Hypersensitivity reactions during treatment with biological agents","volume":"34","author":"Puxeddu","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"2025020515445187500_R31","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1136\/ard.2007.072967","article-title":"Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis","volume":"67","author":"Takeuchi","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"2025020515445187500_R32","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1093\/rheumatology\/kez577","article-title":"Long-term surveillance of biologic therapies in systemic-onset juvenile idiopathic arthritis: data from the German BIKER registry","volume":"59","author":"Klein","year":"2020","journal-title":"Rheumatology"}],"container-title":["Modern Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mr\/advance-article-pdf\/doi\/10.1093\/mr\/roae046\/58010520\/roae046.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/35\/1\/167\/58010520\/roae046.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/35\/1\/167\/58010520\/roae046.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T15:45:20Z","timestamp":1738770320000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mr\/article\/35\/1\/167\/7675293"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,16]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,5,16]]},"published-print":{"date-parts":[[2024,12,25]]}},"URL":"https:\/\/doi.org\/10.1093\/mr\/roae046","relation":{},"ISSN":["1439-7595","1439-7609"],"issn-type":[{"type":"print","value":"1439-7595"},{"type":"electronic","value":"1439-7609"}],"subject":[],"published-other":{"date-parts":[[2025,1]]},"published":{"date-parts":[[2024,5,16]]}}}